JW THERAP-B (02126) surged over 7% in afternoon trading. As of press time, the stock was up 5.76% to HK$4.22, with a turnover of HK$19.47 million. On the news front, on September 20, the National Healthcare Security Administration announced that the expert review work for the 2025 National Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory adjustments has concluded, with all 5 CAR-T drugs, including JW THERAP-B's Binoda, passing the expert review.

Industry insiders generally believe that the collective passage of these 5 CAR-T products through expert review sends a positive signal, demonstrating regulators' determination to improve accessibility of cutting-edge therapies. It's worth noting that CAR-T treatments have consistently failed to enter the basic medical insurance directory due to their high pricing of "over one million yuan per injection."

Currently, CAR-T therapies have essentially formed a diversified payment structure primarily based on commercial medical insurance, supplemented by special disease and drug insurance, and supported by financial installment plans and various assistance programs. JW THERAP-B's Binoda has already been included in over 70 commercial medical insurance products, and the company has responded that its CAR-T products will actively participate in the 2025 medical insurance and commercial insurance innovative drug directory application process.